Table 3

Effect of current glucocorticoid therapy upon non-serious infection (billing code or anti-infective prescription), stratified by mode of administration (oral only, injection only, oral or injection) and dose

Cases (n=13 634)Controls (n=68 170)Crude RR (95% CI)RR, adjusted for age and sex only (95% CI)RR, adjusted for age and sex and DMARD (95% CI)Adjusted RR* (95% CI)
Oral glucocorticoid exposure within past 45 days37.932.51.28 (1.23 to 1.33)1.28 (1.23 to 1.33)1.28 (1.23 to 1.34)1.20 (1.15 to 1.25)
Average daily dose of glucocorticoid therapy
 <5 mg PEQ3.23.11.13 (1.01 to 1.25)1.13 (1.01 to 1.25)1.13 (1.02 to 1.26)1.10 (0.99 to 1.22)
 5–9.9 mg17.817.11.15 (1.09 to 1.20)1.15 (1.09 to 1.20)1.15 (1.10 to 1.21)1.10 (1.04 to 1.16)
 10–14.9 mg9.57.91.33 (1.25 to 1.42)1.33 (1.25 to 1.42)1.34 (1.26 to 1.44)1.25 (1.17 to 1.34)
 15–19.9 mg2.72.11.41 (1.25 to 1.58)1.41 (1.25 to 1.58)1.40 (1.25 to 1.58)1.26 (1.12 to 1.42)
 ≥20 mg4.72.32.33 (2.11 to 2.56)2.33 (2.11 to 2.56)2.27 (2.06 to 2.50)1.85 (1.68 to 2.05)
Systemic glucocorticoid injection within past 45 days2.21.81.18 (1.04 to 1.34)1.18 (1.04 to 1.34)1.18 (1.04 to 1.34)1.07 (0.94 to 1.22)
Any glucocorticoid: oral or injection39.233.71.28 (1.23 to 1.33)1.28 (1.23 to 1.33)1.29 (1.24 to 1.34)1.19 (1.14 to 1.24)
  • Numbers are percentages unless otherwise stated.

  • * Adjusted for all a priori confounders listed in table 2.

  • DMARD, disease-modifying antirheumatic drug; PEQ, prednisolone equivalent dose.